Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
暂无分享，去创建一个
R. Fanin | P. Piccaluga | G. Martinelli | D. Russo | M. Tiribelli | D. Damiani | A. Candoni | E. Toffoletti | A. Michelutti | Alexia Chiarvesio | M. Malagola | E. Simeone